Merck's New COVID Pill Is a Disaster

What does the research say about the effectiveness of molnupiravir? Read the data here.

STORY AT-A-GLANCE

• An advisory panel to the U.S. Food and Drug Administration voted to grant emergency authorization to Merck’s oral COVID-19 pill molnupiravir (Lagevrio) — by a narrow 13-to-10 margin

• Among those who received the drug, the rate of all-cause hospitalization or death was 6.8%, compared to 9.7% in the placebo group — a relative risk reduction…